Vertex’s R&D Leader On Sickle Cell Challenges And ‘Out-Innovating’ Itself
David Altshuler Outlines What Sets The Biotech Apart
A few years ago, investors were calling on Vertex to buy in late-stage innovation, but its focus on audacious drug development goals looks set to pay off with a groundbreaking CRISPR-based sickle cell disease cell therapy approaching the market. Its R&D head David Altshuler talked to Scrip about its approach.
